Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8043766 | 0.83 | L3MBTL1 (0.52) | ALDH1A1CYP1A2POLBMAPT | |
| SCHEMBL28185162 | 0.81 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL8043762 | 0.80 | MTNR1B (0.52) | ALDH1A1MTNR1AMTNR1BMAPT | |
| SCHEMBL1743175 | 0.78 | PLAU (0.33) | ALDH1A1CYP1A2POLBMAPT | |
| SCHEMBL28100309 | 0.77 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10TSHR | |
| SCHEMBL221066 | 0.77 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MAPK1POLBMAPT | |
| SCHEMBL7406905 | 0.77 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10TSHR | |
| SCHEMBL4066831 | 0.77 | HSD17B10 (0.52) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10TSHR | |
| SCHEMBL7841883 | 0.77 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1CYP1A2HSD17B10TSHR | |
| SCHEMBL4837973 | 0.76 | SNCA (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000045-A1 | 1,4-DISUBSTITUTED PIPERAZINES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006382-A1 | 1,4-DISUBSTITUTED PIPERAZINES | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | claimed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| EP-2388297-B1 | CURABLE COMPOSITION AND CURED OBJECT FORMED THEREFROM | KANEKA CORP (JP) | 2020-08-19 | — | — | EP | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-1990371-A1 | CURABLE COMPOSITION | Kaneka Corporation (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1654229-B1 | PIPERIDINE DERIVATIVES AS CCR5 RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| EP-1000045-A1 | 1,4-DISUBSTITUTED PIPERAZINES | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006382-A1 | 1,4-DISUBSTITUTED PIPERAZINES | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | disclosed |
| EP-0227980-B1 | FLUORESCENT AROXYSUBSTITUTED 3,4,9,10-PERYLENETETRACARBOXYLIC ACID-DIIMIDES AND THEIR USE FOR THE CONCENTRATION OF LIGHTS IN SMALL AREAS | BASF Aktiengesellschaft (DE) | 1991-10-09 | — | — | EP | disclosed |
| US-4845223-A | FLUORESCENT PERYLENE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
| EP-0227980-A2 | Fluorescent aroxysubstituted 3,4,9,10-perylenetetracarboxylic acid-diimides and their use for the concentration of lights in small areas | BASF Aktiengesellschaft (DE) | 1987-07-08 | — | — | EP | disclosed |
| US-4379934-A | Process for two-dimensionally concentrating light, and novel perylene-3,4,9,10-tetracarboxylic acid diimides | BASF AKTIENGESELLSCHAFT (DE) | 1983-04-12 | — | — | US | disclosed |
| EP-0033079-A1 | Perylene-3,4,9,10-tetracarboxylic-acid diimides and their use | BASF Aktiengesellschaft (DE) | 1981-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SMN1; SMN2 4049/4885ALDH1A1 1244/4885CDK1 3738/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SMN1; SMN2 4049/4885ALDH1A1 1244/4885CDK1 3738/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | SMN1; SMN2 4224/4885ALDH1A1 1118/4885CDK1 4143/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SMN1; SMN2 4049/4885ALDH1A1 1244/4885CDK1 3738/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | SMN1; SMN2 4163/4885ALDH1A1 1518/4885CDK1 3934/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | SMN1; SMN2 4076/4885ALDH1A1 1279/4885CDK1 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.